Hsp90-targeted miRNA-liposomal formulation for systemic antitumor effect

Area of Science:

• Oncology
• Molecular Biology
• Gene Therapy

Background:

• Heat shock protein 90 (Hsp90) is over-expressed in cancer cells, maintaining critical proteins.
• Current small molecule inhibitors of Hsp90 often cause non-specific toxicity due to improper targeting.
• Cancer cells exhibit compromised Hsp90 chaperone activity, enabling cancer-specific GR-transactivation.

Purpose of the Study:

• To develop a novel anticancer strategy by selectively compromising Hsp90 in cancer cells.
• To investigate the efficacy of a GR-targeted lipoplex delivering artificial miRNA against Hsp90 (amiR-Hsp90) for cancer gene therapy.
• To evaluate the therapeutic potential of depleting Hsp90 for tumor regression.

Main Methods:

• Development of a GR-targeted lipoplex formulation carrying amiR-Hsp90.
• In vivo delivery of the lipoplex in tumor-bearing mice.
• Assessment of Hsp90 levels, client protein expression (Akt, VEGFR2), p53 levels, apoptosis, and tumor volume changes.

Main Results:

• GR-mediated delivery of amiR-Hsp90 lipoplex selectively depleted Hsp90 in tumors.
• Down-regulation of Hsp90 clients (Akt, VEGFR2) and up-regulation of wild-type p53 were observed in tumors.
• Significant apoptosis induction in tumor mass and angiogenic vessels, leading to substantial tumor volume reduction.

Conclusions:

• GR-targeted lipoplex delivering amiR-Hsp90 represents a promising gene therapy strategy for cancer.
• Selective Hsp90 depletion via this method offers a targeted approach with reduced toxicity.
• This approach effectively inhibits tumor growth by inducing apoptosis and down-regulating key oncogenic pathways.